Within the game of representative musical chairs prompted by Sanofi CEO Olivier Brandicourt’s exit, Novartis lost its pharma head, Paul Hudson. However, it was in a position with a replacement: Marie-France Tschudin, who joined the corporate in January 2017 from Celgene.
Tschudin takes the wand from Hudson as Novartis revs up a few new launches and builds out its holdings in part-dozen healing fields while joining virtual through its complete operation. She’ll report back to CEO Vas Narasimhan, who’s somewhat new to his functions and working on marking his stamp on the corporation.
In the meantime, her promotion to president of Novartis Pharmaceuticals places Tschudin a number of the most highly positioned women within the pharma trade. She joins Novartis Oncology leader Susanne Schaffert and General Counsel Shannon Klinger at the Swiss drugmaker’s government committee, and that trio of female leaders makes Novartis’ best management crew more diverse, gender-wise, than those of different pharma.
She’ll have lots to do at Novartis, regardless that, as it progresses into the budding gene treatment arena while introducing new meds—and maintaining a tally of recent launches—in further traditional fields. Last month, Narasimhan talked up 25 new releases its pharma unit’s preparing over the next a couple of years, along with ten possible blockbusters.
Amongst those releases is Zolgensma, Novartis’ brand-new gene treatment, and the costliest drug ever. Priced at $2.1 million, the spinal muscular atrophy remedy is trying out new waters in price-based payer offers and installment-plan payment models—not to point out proving multimillion-dollar price tickets.